Edarbi

Edarbi

Manufacturer:

Celltrion Healthcare

Distributor:

DKSH
Concise Prescribing Info
Contents
Azilsartan medoxomil (as K)
Indications/Uses
Essential HTN in adults.
Dosage/Direction for Use
Initially 40 mg once daily. May be increased to a max of 80 mg once daily as necessary.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Concomitant use w/ aliskiren. Pregnancy (2nd & 3rd trimester).
Special Precautions
CHF, severe renal & hepatic impairment, ESRD, renal artery stenosis. Ischaemic cardiomyopathy or ischaemic cerebrovascular disease. Vol- &/or salt-depleted patients, primary hyperaldosteronism. Monitor serum K in patients taking K-sparing diuretics, salt substitutes containing K & drugs that increase K levels (eg, heparin) & creatinine levels in patients w/ renal impairment & DM. Aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy.
Adverse Reactions
Dizziness, diarrhoea, increased blood creatinine.
Drug Interactions
Reversibly increases serum conc & toxicity of lithium; attenuated antihypertensive effects & risk of worsening of renal function may occur w/ NSAIDs. Hyperkalemia w/ K-sparing diuretics & K supplements.
ATC Classification
C09CA09 - azilsartan medoxomil ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Presentation/Packing
Form
Edarbi tab 40 mg
Packing/Price
2 × 14's
Form
Edarbi tab 80 mg
Packing/Price
2 × 14's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in